BD advances iliac artery treatment with the Revello Vascular Covered Stent across the European Union – Becton, Dickinson and Company
BD (Becton, Dickinson and Company) announced it has obtained CE Marking for the Revello Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries. This advancement arrives at a pivotal moment, as lower‑extremity peripheral artery disease (PAD), which iliac artery disease is a key component—drives a substantial disability burden across the EU’s aging population. The Revello Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries.
Following receipt of the CE Mark, the Revello Stent was introduced at the LINC 2026 congress in Germany, where physicians discussed its potential impact on iliac interventions.
Physician and Angiologist, Dr. Michael Lichtenberg highlighted the ongoing AGILITY clinical trial, which is evaluating the device’s performance in patients with PAD. This trial is a prospective, multi-center study led by global principal investigator, Dr. Sean Lyden, chairman of the Department of Vascular Surgery at Cleveland Clinic in Cleveland, Ohio, and Dr. Lichtenberg, European principal investigator. “With the Revello Stent, we have a very good new option for the treatment of iliac arteries,” said Dr. Lichtenberg. “It stands out for its high radial force and low profile. The triaxial delivery system allows for very easy and precise placement.”
The Revello Stent will be launched in CE-mark-accepting countries across Europe. In the United States, it is an investigational device limited by U.S. law to investigational use only.
“The CE Marking of the Revello Stent is a significant advancement towards helping physicians treating complex iliac artery disease,” said Rima Alameddine, worldwide president, BD Interventional – Peripheral Intervention. “The Revello Vascular Covered Stent was built to raise the standard of iliac artery revascularization, expand the growing BD peripheral vascular portfolio and reinforce the company’s commitment to delivering clinically relevant innovation for physicians treating complex PAD across EU and EEA countries.”
